Clinical research of Omalizumab in treatment of children with allergic diseases / 国际儿科学杂志

ABSTRACT

Objective:To investigate the therapeutic effect of Omalizumab in children suffering from multiple allergic diseases.Methods:The clinical data of children treated with Omalizumab in the Affiliated BenQ Hospital of Nanjing Medical University from September 2020 to September 2022 were retrospectively analyzed.Their gender, age, type of allergic disease, serum total IgE(TIgE), skin prick test and/or serum allergen specific IgE(sIgE)levels, Omalizumab dosage, therapeutic effect and adverse drug reactions were analyzed.Results:Forty-three children(male/female, 24/19)were treated with Omalizumab.The age is(9.3±2.5)years.Types of allergic diseases: 43 cases of asthma(100%), 43 cases of allergic rhinitis(100%), 5 cases of allergic conjunctivitis(11.6%), 18 cases of atopic dermatitis(41.9%), 1 case of milk protein allergy(2.3%). All the 43 patients had elevated TIgE[(613.27±616.21)Ku/L]. Allergen testing for all the children were positive, with dust mite allergy accounting for the highest proportion(93%). After treatment, the frequency of wheezing attacks was reduced and the nasal symptoms were alleviate in 43 children with asthma combined with allergic rhinitis; 5 children with allergic conjunctivitis had significantly improved symptoms of redness and itching; the skin itching in 17 children with atopic dermatitis was alleviated, and 1case had poor improvement; 1 child with milk allergy could tolerate dairy products.Conclusion:There are significant therapeutic benefits of Omalizumab in children with multiple allergic diseases.